Management Pediatric Stroke
The supportive measures for acute chemic stroke (IIS) should include control of fever, maintenance of normal oxygenation, control of systemic hypertension and normalization of serum glucose. It is also reasonable to treat dehydration and anemia in children with stroke. In individuals with antibacterial hemorrhage (ICC) , the markedly low platelet counts should be corrected. Replacement of the deficient coagulation factors should be given to neonates with ICC.
For Individuals with vitamin K-dependent coagulation disorder, Vitamin K should be administer. Higher doses maybe required In neonates with factor deficiencies resulting from maternal dedications. Patients who develop hydrocephalus after an ICC should undergo ventricular drainage and later shunting if significant hydrocephalus persists. For neurological dysfunction, the use of rehabilitation and ongoing physical therapy is reasonable.
It is also reasonable to give foliate and vitamin B to individual with an MONTH mutation in an effort to normalize homogeneities levels. For one that have intradepartmental brain hematite, evacuation of the hematite can be done to reduce very high interracial pressure. In selected neonates with severe hieroglyphic disorder, multiple cerebral or systemic embolism, or propagating cerebral venous sinus thrombosis (C.V.) despite supportive therapy, anticoagulation with low molecular weight heparin (ALPHA) or unformulated heparin (UHF) may be considered.
For long-term anticoagulation of children with a substantial risk of recurrent cardiac embolism, C.V. and selected hyperbolically states, ALPHA and warring can be used. For the secondary prevention of IIS , aspirin is frequently used in children whose infarction is not due to sickle cell disease and in children who are are not noon to have a high risk of recurrent embolism or severe hyperbolically disorder.
A dose of 3 to 5 MGM/keg/day is a reasonable initial aspirin dose for stroke prevention in children. If dose-related side effects occur with this aspirin dose, a dose reduction to 1 to 3 MGM/keg may be considered. It is also reasonable for those children to take vaccination for variable and influenza in an effort to reduce the risk of Rye’s syndrome. In selected children with C.V., tissue plainspoken activator can be considered. Reference: http://stroke. Journals. Org/content/39/9/2644. Full#TTT